Intravenous Thrombolytics for Ischemic Stroke

Neurotherapeutics

Volumn 8, Issue 3, 2011, Pages 388-399

  Barreto, Andrew D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Fibrinolytic; Intravenous thrombolysis; Ischemia; Stroke; Thrombolytics; Treatment

Indexed keywords

ALBUMIN; ALTEPLASE; ARGATROBAN; DESMOTEPLASE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; MAGNESIUM; PLASMIN; PLASMINOGEN ACTIVATOR; PROUROKINASE; RECOMBINANT PLASMINOGEN ACTIVATOR; RETEPLASE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ALLERGIC REACTION; ARTERY OCCLUSION; ARTERY THROMBOSIS; BLOOD CLOT LYSIS; BLOOD CLOTTING; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN PERFUSION; DEVICE THERAPY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG FEVER; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEMATOTHORAX; HUMAN; HYPOTENSION; HYPOTHERMIA; LOW DRUG DOSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RECANALIZATION; REPERFUSION; REVIEW; RISK ASSESSMENT; STROKE; THROMBUS;

BRAIN INFARCTION; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENTRICULAR; ISCHEMIA; STROKE; THROMBOLYTIC THERAPY;

EID: 79960789806     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-011-0049-x     Document Type: Review

References (79)

1. Mackay JMG. The atlas of heart disease and stroke. London: World Stroke Organization; 2004.
2. Asplund KSB, Peltonem M. From the twentieth to the twenty-first century: a public health perspective on stroke. In: Ginsberg MD, ed. Cerebrovascular Disease Pathophysiology, Diagnosis and Management. Malden, Mass: Blackwell Science; 1998.
3. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation121: e46-e215.
4. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998; 91: 2645-2657.
5. Colman RW, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott Williams & Wilkins; 2006.
6. Loren M, Garcia Frade LJ, Torrado MC, Navarro JL. Thrombus age and tissue plasminogen activator mediated thrombolysis in rats. Thromb Res 1989; 56: 67-75.
7. Collen D. On the regulation and control of fibrinolysis. Edward Kowalski memorial lecture. Thromb Haemost 1980; 43: 77-89.
8. Tillett WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933; 58: 485-502.
9. Christensen LR, Macleod CM. A proteolytic enzyme of serum: characterization, activation, and reaction with inhibitors. J Gen Physiol 1945; 28: 559-583.
10. Johnson AJ, Tillett WS. The lysis in rabbits of intravascular blood clots by the streptococcal fibrinolytic system (streptokinase). J Exp Med 1952; 95: 449-464.
11. Fletcher AP, Alkjaersig N, Smyrniotis FE, Sherry S. The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians 1958; 71: 287-296.
12. Collen D. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy. J Cell Biochem 1987; 33: 77-86.
13. Paciaroni M, Medeiros E, Bogousslavsky J. Desmoteplase. Expert Opin Biol Ther 2009; 9: 773-778.
14. Fletcher AP, Sherry S, Alkjaersig N, Smyrniotis FE, Jick S. The maintenance of a sustained thrombolytic state in man. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest 1959; 38: 1111-1119.
15. Schmutzler R, Heckner F, Kortge P, et al. Thrombolytic therapy of recent myocardial infarction. I. Introduction, plan of trial, general clinical results. Ger Med Mon 1966; 11: 308-314.
16. Bett JHN, Castaldi PA, Hale GS, et al. Australian multicentre trial of streptokinase in acute myocardial infarction. Lancet 1973; 301: 57-60.
17. Aber CP, Bass NM, Berry CL, et al. Streptokinase in acute myocardial infarction: a controlled multicentre study in the United Kingdom. Br Med J 1976; 2: 1100-1104.
18. Dioguardi N, Lotto A, Levi GF, et al. Controlled trial of streptokinase and heparin in acute myocardial infarction. Lancet 1971; 2: 891-895.
19. Streptokinase in acute myocardial infarction. European Cooperative Study Group for streptokinase treatment in acute myocardial infarction. N Engl J Med 1979; 301: 797-802.
20. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo italiano per lo studio della streptochinasi nell'infarto miocardico (GISSI). Lancet 1986; 327: 397-402.
21. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12, 490 patients with acute myocardial infarction. Gruppo italiano per lo studio della sopravvivenza nell'infarto miocardico. Lancet 1990; 336: 65-71.
22. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41, 299 cases of suspected acute myocardial infarction. ISIS-3 (third international study of infarct survival) collaborative group. Lancet 1992; 339: 753-770.
23. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329: 673-682.
24. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to update the 1999 guidelines for coronary artery bypass graft surgery). J Am Coll Cardiol 2004; 44: e213-e310.
25. Sussman BJ, Fitch TS. Thrombolysis with fibrinolysin in cerebral arterial occlusion. J Am Med Assoc 1958; 167: 1705-1709.
26. Meyer JS, Gilroy J, Barnhart MI, Johnson JF. Therapeutic thrombolysis in cerebral thromboembolism. Double-blind evaluation of intravenous plasmin therapy in carotid and middle cerebral arterial occlusion. Neurology 1963; 13: 927-937.
27. Meyer JS, Gilroy J, Barnhart MI, Johnson JF. Anticoagulants plus streptokinase therapy in progressive stroke. JAMA 1964; 189: 373.
28. Fletcher AP, Alkjaersig N, Lewis M, et al. A pilot study of urokinase therapy in cerebral infarction. Stroke 1976; 7: 135-142.
29. del Zoppo GJ, Ferbert A, Otis S, et al. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. A pilot study. Stroke 1988; 19: 307-313.
30. Hacke W, Zeumer H, Ferbert A, Bruckmann H, del Zoppo GJ. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988; 19: 1216-1222.
31. Thrombolytic therapy in thrombosis: A National Institutes of Health Consensus Development Conference. Ann Intern Med 1980; 93: 141-144.
32. Thrombolytic therapy with streptokinase in acute ischemic stroke. The multicenter acute stroke trial - Europe study group. N Engl J Med 1996; 335: 145-150.
33. Crowell RM, Marcoux FW, DeGirolami U. Variability and reversibility of focal cerebral ischemia in unanesthetized monkeys. Neurology 1981; 31: 1295-1302.
34. Zeumer H. Vascular recanalizing techniques in interventional neuroradiology. J Neurol 1985; 231: 287-294.
35. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42: 976-982.
36. del Zoppo GJ, Zeumer H, Harker LA. Thrombolytic therapy in stroke: possibilities and hazards. Stroke 1986; 17: 595-607.
37. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak JA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 1985; 230: 1289-1292.
38. Lyden PD, Madden KP, Clark WM, Sasse KC, Zivin JA. Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]. Stroke 1990; 21: 1589-1593.
39. Brott TG, Haley EC Jr., Levy DE, et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23: 632-640.
40. Haley EC Jr., Levy DE, Brott TG, et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992; 23: 641-645.
41. von Kummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke 1992; 23: 646-652.
42. del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 992; 32: 78-86.
43. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-1025.
44. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-1587.
45. Grotta JC, Alexandrov AV. tPA-associated reperfusion after acute stroke demonstrated by spect. Stroke 1998; 29: 429-432.
46. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NIND t-PA stroke trial. Stroke 1997; 28: 2119-2125.
47. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997; 28: 2109-2118.
48. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders And Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999; 340: 1781-1787.
49. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: The NINDS rt-PA stroke study. Neurology 2000; 55: 1649-1655.
50. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 2004; 61: 1066-1070.
51. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-1251.
52. Ingall TJ, O'Fallon WM, Asplund K, et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 2004; 35: 2418-2424.
53. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-774.
54. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4. 5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
55. del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009; 40: 2945-2948.
56. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-1703.
57. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre acute stroke trial--italy (MAST-I) group. Lancet 1995; 346: 1509-1514.
58. Donnan GA, Davis SM, Chambers BR, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian streptokinase (ASK) trial study group. JAMA 1996; 276: 961-966.
59. van De Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial. Lancet 1999; 354: 716-722.
60. Thomas GR, Thibodeaux H, Errett CJ, et al. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke 1994; 25: 2072-2079.
61. Chapman DF, Lyden P, Lapchak PA, Nunez S, Thibodeaux H, Zivin J. Comparison of TBK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke 2001; 32: 748-752.
62. Haley EC Jr., Lyden PD, Johnston KC, Hemmen TM. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005; 36: 607-612.
63. Haley EC Jr., Thompson JL, Grotta JC, et al. Phase IIb/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 41: 707-711.
64. Weaver WD. Results of the RAPID 1 and RAPID 2 thrombolytic trials in acute myocardial infarction. Eur Heart J1996; 17(suppl E): 14-20.
65. Yenari MA, Lee LK, Beaulieu C, et al. Thrombolysis with reteplase, an unglycosylated plasminogen activator variant, in experimental embolic stroke. J Stroke Cerebrovasc Dis 1998; 7: 179-186.
66. Qureshi AI, Ali Z, Suri MF, et al. Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke. Neurosurgery 2001; 49: 41-50.
67. Sugg RM, Noser EA, Shaltoni HM, et al. Intra-arterial reteplase compared to urokinase for thrombolytic recanalization in acute ischemic stroke. AJNR Am J Neuroradiol 2006; 27: 769-773.
68. Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003; 34: 537-543.
69. Reddrop C, Moldrich RX, Beart PM, et al. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 2005; 36: 1241-1246.
70. Hacke W, Albers G, Al-Rawi Y, et al. The desmoteplase in acute ischemic stroke trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36: 66-73.
71. Furlan AJ, Eyding D, Albers GW, et al. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006; 37: 1227-1231.
72. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): A prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009; 8: 141-150.
73. H. Lundbeck A/S. Efficacy and safety study of desmoteplase to treat acute ischemic stroke (DIAS-3). In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available at: http://clinicaltrials. gov/show/NCT00790920 NLM Identifier: NCT00790920. Accessed: November 14, 2010.
74. Lundbeck H A/S. Efficacy and safety study of desmoteplase to treat acute ischemic stroke (DIAS-4). In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available at: http://clinicaltrials. gov/show/NCT00856661 NLM Identifier: NCT00856661. Accessed: November 14, 2010.
75. Marder VJ, Landskroner K, Novokhatny V, et al. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 2001; 86: 739-745.
76. Marder VJ, Jahan R, Gruber T, Goyal A, Arora V. Thrombolysis with plasmin: Implications for stroke treatment. Stroke 2010; 41: S45-S49.
77. Talecris Biotherapeutics. A safety and dose finding study of plasmin (human) administered into the middle cerebral artery of stroke patients. In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available at: http://clinicaltrials. gov/show/NCT01014975 NLM Identifier: NCT01014975. Accessed: November 14, 2010.
78. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002; 59: 862-867.
79. Mustanoja S, Meretoja A, Putaala J, et al. Outcome by stroke etiology in patients receiving thrombolytic treatment: Descriptive subtype analysis. Stroke 2011; 42: 102-106.